NSG 6005 Pharmacology Weeks 1–3 Quiz – 100% Correct Answers (OperationFNP Class 11)

NSG 6005 PHARM WEEKS 1-3 QUIZ
(FROM OPERATIONFNP CLASS 11)
TEST WITH 100% CORRECT ANSWERS




Genetic bpolymorphisms baccount bfor bdifferences bin bmetabolism, bincluding:

1. bPoor bmetabolizers, bwho black ba bworking benzyme

2. bIntermediate bmetabolizers, bwho bhave bone bworking, bwild-type ballele band bone bmutant
ballele


3. bExtensive bmetabolizers, bwith btwo bnormally bfunctioning balleles

4. bAll bof bthe babove b- bcorrect banswer-4. bAll bof bthe babove

Up bto b21% bof bAsians bare bultra-rapid b2D6 bmetabolizers, bleading bto:

1. bA bneed bto bmonitor bdrugs bmetabolized bby b2D6 bfor btoxicity

2. bIncreased bdosages bneeded bof bdrugs bmetabolized bby b2D6, bsuch bas bthe bselective
bserotonin breuptake binhibitors


3. bDecreased bconversion bof bcodeine bto bmorphine bby bCYP b2D6

4. bThe bneed bfor blowered bdosages bof bdrugs, bsuch bas bbeta bblockers b- bcorrect banswer-2.
bIncreased bdosages bneeded bof bdrugs bmetabolized bby b2D6, bsuch bas bthe bselective
bserotonin breuptake binhibitors


Rifampin bis ba bnonspecific bCYP450 binducer bthat bmay:

1. bLead bto btoxic blevels bof brifampin band bmust bbe bmonitored bclosely

2. bCause btoxic blevels bof bdrugs, bsuch bas boral bcontraceptives, bwhen bcoadministered

,3. bInduce bthe bmetabolism bof bdrugs, bsuch bas boral bcontraceptives, bleading bto btherapeutic
bfailure


4. bCause bnonspecific bchanges bin bdrug bmetabolism b- bcorrect banswer-3. bInduce bthe
bmetabolism bof bdrugs, bsuch bas boral bcontraceptives, bleading bto btherapeutic bfailure


Inhibition bof bP-glycoprotein bby ba bdrug bsuch bas bquinidine bmay blead bto:

1. bDecreased btherapeutic blevels bof bquinidine

2. bIncreased btherapeutic blevels bof bquinidine

3. bDecreased blevels bof ba bcoadministered bdrug, bsuch bas bdigoxin, bthat brequires bP-
glycoprotein bfor babsorption band belimination

4. bIncreased blevels bof ba bcoadministered bdrug, bsuch bas bdigoxin, bthat brequires bP-
glycoprotein bfor babsorption band belimination b- bcorrect banswer-4. bIncreased blevels bof ba
bcoadministered bdrug, bsuch bas bdigoxin, bthat brequires bP-
glycoprotein bfor babsorption band belimination

Warfarin bresistance bmay bbe bseen bin bpatients bwith bVCORC1 bmutation, bleading bto:

1. bToxic blevels bof bwarfarin bbuilding bup

2. bDecreased bresponse bto bwarfarin

3. bIncreased brisk bfor bsignificant bdrug binteractions bwith bwarfarin

4. bLess brisk bof bdrug binteractions bwith bwarfarin b- bcorrect banswer-2. bDecreased bresponse
bto bwarfarin


Genetic btesting bfor bVCORC1 bmutation bto bassess bpotential bwarfarin bresistance bis
brequired bprior bto bprescribing bwarfarin.


1. bTrue

2. bFalse b- bcorrect banswer-2. bFalse

Pharmacogenetic btesting bis brequired bby bthe bU.S. bFood band bDrug bAdministration bprior
bto bprescribing:


1. bErythromycin

2. bDigoxin

3. bCetuximab

4. bRifampin b- bcorrect banswer-3. bCetuximab

Carbamazepine bhas ba bBlack bBox bWarning brecommending btesting bfor bthe bHLA-

, B*1502 ballele bin bpatients bwith bAsian bancestry bprior bto bstarting btherapy bdue bto:

1. bDecreased beffectiveness bof bcarbamazepine bin btreating bseizures bin bAsian bpatients bwith
bthe bHLA-B*1502 ballele


2. bIncreased brisk bfor bdrug binteractions bin bAsian bpatients bwith bthe bHLA-B*1502 ballele

3. bIncreased brisk bfor bStevens-Johnson bsyndrome bin bAsian bpatients bwith bHLA-B*1502
ballele


4. bPatients bwho bhave bthe bHLA-B*1502 ballele bbeing bmore blikely bto bhave ba bresistance
bto bcarbamazepine b- bcorrect banswer-3. bIncreased brisk bfor bStevens-Johnson bsyndrome bin
bAsian bpatients bwith bHLA-B*1502 ballele


A bgenetic bvariation bin bhow bthe bmetabolite bof bthe bcancer bdrug birinotecan bSN-38 bis
binactivated bby bthe bbody bmay blead bto:


1. bDecreased beffectiveness bof birinotecan bin bthe btreatment bof bcancer

2. bIncreased badverse bdrug breactions, bsuch bas bneutropenia

3. bDelayed bmetabolism bof bthe bprodrug birinotecan binto bthe bactive bmetabolite bSN-38

4. bIncreased bconcerns bfor birinotecan bbeing bcarcinogenic b- bcorrect banswer-2. bIncreased
badverse bdrug breactions, bsuch bas bneutropenia


Patients bwho bhave ba bpoor bmetabolism bphenotype bwill bhave:

1. bSlowed bmetabolism bof ba bprodrug binto ban bactive bdrug, bleading bto baccumulation bof
bprodrug


2. bAccumulation bof binactive bmetabolites bof bdrugs

3. bA bneed bfor bincreased bdosages bof bmedications

4. bIncreased belimination bof ban bactive bdrug b- bcorrect banswer-1. bSlowed bmetabolism bof ba
bprodrug binto ban bactive bdrug, bleading bto baccumulation bof bprodrug


Ultra-rapid bmetabolizers bof bdrugs bmay bhave:

1. bTo bhave bdosages bof bdrugs badjusted bdownward bto bprevent bdrug baccumulation

2. bActive bdrug brapidly bmetabolized binto binactive bmetabolites, bleading bto bpotential
btherapeutic bfailure


3. bIncreased belimination bof bactive, bnonmetabolized bdrug

4. bSlowed bmetabolism bof ba bprodrug binto ban bactive bdrug, bleading bto ban baccumulation
bof bprodrug b- bcorrect banswer-2. bActive bdrug brapidly bmetabolized binto binactive
bmetabolites, bleading bto bpotential btherapeutic bfailure